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ABSTRACT
Preeclampsia, a pregnancy-specifi c syndrome character-
ized by hypertension, proteinuria and oedema, resolves 
on placental delivery. Its pathogenesis is thought to be 
associated to a hypoxic placenta. Placental hypoxia is 
responsible for the maternal vascular dysfunction via the 
increased placental release of anti-angiogenic factors such 
as soluble fl t1 and endoglin. These soluble receptors bind 
VEGF, PLGF and TGFβ1 and 3 in the maternal circulation, 
causing endothelial dysfunction in many maternal tissues.
Despite these recent and important new molecular 
fi ndings, it is important to consider that normal pregnancy is 
also characterized by systemic infl ammation, oxidative stress 
and alterations in levels of angiogenic factors and vascular 
reactivity. Both the placenta and maternal vasculatures are 
major sources of reactive oxygen and nitrogen species which 
can produce powerful pro-oxidants that covalently modify 
proteins and alter vascular function in preeclampsia. Finally, 
the recent demonstration of activating auto-antibodies 
to the Angiotensin 1 receptor that experimentally play a 
major pathogenic role in preeclampsia further indicates the 
pleiotropism of aetiologies of this condition.
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INTRODUCTION
Preeclampsia (PE), which affects 3 to 5 % of all pregnancies, 
is still a leading cause of materno-foetal morbidity and mor-
tality. It is a pregnancy-specifi c syndrome that resolves with 
placental delivery. PE is defi ned by the onset of hypertension 
and proteinuria (≥ 0,3g/24h) after 20 weeks of gestation, with 
or without oedema. In severe forms of PE, some clinical and 
biological complications occur: headache, epigastric pain, visual 
disorders, thrombocytopenia and alteration of liver enzymes. 
These clinical manifestations are caused by the mild to severe 
microangiopathy that affects target organs like the liver, the 
brain, the kidneys and the placenta (1). 
PE can lead to premature delivery, intra-uterine growth re-
striction (IUGR), neurological hypoxic lesions in the newborn 
and in utero foetal death. Complications on the maternal side 
are also severe, like renal or hepatic failure, the “HELLP syn-
drome” (Haemolysis, Elevated Liver enzymes, Low Platelet 
count), seizure, stroke and even maternal death.
RISK FACTORS
Numbers of risk factors have been described (2). They can 
be classifi ed in 5 categories:
• Genetic factors (family or personal history of PE or hyper-
tension)
• Immunological factors (primi-paternity, sperm exposure, 
primi-parity)
• Physiological factors (age, ethnic group, BMI, birth weight, 
gestational age at birth)
• Pregnancy-related factors (multiple pregnancy, foetal 
malformation, urinary tract infection)
• Environmental factors (tobacco, alcohol, drugs, caffeine, 
life in altitude, lifestyle, socio-economic level)
PHYSIOPATHOLOGY
Physiopathology of PE is complicated and numbers of stud-
ies try to elucidate the mechanisms leading to PE. Several the-
ories have been described these last years. Among them, the 
most commonly accepted is the “placental vascular disease”.
« Two-stages disorder »
PE is actually considered to be the clinical expression of a 
maternal endothelial disease which is related to the presence 
of a placenta and, more precisely, related to an insuffi cient tro-
phoblastic invasion of the uterine spiral arteries.
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This pathology seems to progress in two stages: pre-clinical 
and clinical. In the fi rst one, precarity of the placental devel-
opment and of its maternal blood support is responsible of 
placental hypoxia, oxidative stress and systemic maternal in-
fl ammatory stress. In the second stage, placental hypoxia leads 
to maternal symptoms of PE, hypertension and proteinuria, as 
well as associated complications (3).
Recently, some authors have proposed a more complex the-
ory in which they associate the two stages previously described 
with maternal constitutional factors, indicating that the defec-
tive placental perfusion is not suffi cient to cause PE. Also, as 
most of the metabolic changes observed in PE are exaggera-
tions of the changes observed in all pregnancies, it is possi-
ble that, in a patient with predisposing factors, the “normal” 
changes of pregnancy will be suffi cient to induce the second 
phase of PE (4).
First stage: defective placentation
Recently, it was reported that 36 differentially expressed 
genes are detectable at 10 weeks gestation in the placentas 
of women who later develop PE (57). Thirty-one genes were 
down-regulated, many of which were related to infl ammation/
immunoregulation and cell motility. Decidual gene dysregula-
tion was prominent, but no evidence was found for alterations 
in hypoxia, angiogenic and oxidative stress regulated genes. 
This dysregulation of gene expression in the early placentas 
of women, ~ 6 months before PE manifests clinically, rein-
forces the hypothesis of a placental origin of this disorder, and 
suggests that placentation in PE is compromised in the fi rst 
trimester by maternal and foetal immune dysregulation, ab-
normal decidualization, or both, thereby impairing trophoblast 
invasion. It is not surprising that early gene dysregulation does 
not involve hypoxia or angiogenic related genes since during 
the fi rst 12 weeks of pregnancy, foetal development occurs un-
der low oxygen tension.
Trophoblastic invasion is special to human placentation. 
It is limited in depth, ending in the intern third of the myo-
metrium and is orientated to the spiral arteries. During nor-
mal pregnancy, extra-villous trophoblast invades spiral arteries, 
forms “plugs” and obstructs the arterial lumen until the 11th 
week of gestation, allowing only plasma to penetrate in the 
inter-villous chamber (5-7). This particular placental perfusion 
protects in fact the foetus in organogenesis from the damaging 
and teratogenous effects of oxygen free radicals. From the 12th 
week of pregnancy, the “vascular trophoblastic plugs” open and 
maternal blood can penetrate the intervillous chamber.
Invasion and remodelling of spiral arteries by invasive tro-
phoblast are necessary for a good placental function. Indeed, 
trophoblastic cells progressively replace vascular endothelium 
by acquiring a “pseudo-vascular” phenotype and the outer 
layer of smooth muscle cells normally disappears, leading to 
large, high capacitance vessels, without sensitivity to vasoac-
tive stimuli (8,9). These changes are essential to allow adequate 
blood supply to the placenta.
In PE, trophoblast fails to acquire the invasive vascular phe-
notype and cannot invade the myometrial part of spiral arteries 
(9, 10). Remodelling of these arteries is thus limited, with fail-
ure of conversion of high resistance to high capacitance vessels. 
Defective placentation is thus associated with a reduced perfu-
sion which leads to placental ischaemia despite evolutive preg-
nancy (11). The initial events responsible of these changes are 
still unknown. They probably implicate immunological, genetic 
and vascular maternal factors as well as foetal and placental 
factors.
Second phase: maternal syndrome
More and more publications mention that the clinical man-
ifestations of PE are explicated by the endothelial dysfunction 
caused by some factors secreted in maternal circulation by the 
hypoxic placenta. This endothelial dysfunction is defi ned by 
increased vascular permeability, excessive lipid peroxydation, 
platelets activation, coagulation’s cascade activation, oxidative 
stress and changes in the balance of vasoactive factors in fa-
vour of vasoconstriction (12-14). 
Microparticles
Normal placenta releases trophoblastic particles in mater-
nal circulation (15,16). These particles are «subcellular» vesi-
cles with a diameter of 100 to 200 nm and correspond to parts 
of syncitiotrophoblast membrane, fragments of cytokeratin, 
soluble RNA, foetal DNA and trophoblastic cells. These mic-
roparticles are pro-infl ammatory and their release is highly en-
hanced by the placenta of preeclamptic patients. They interact 
with endothelial and immune system cells and they could thus 
participate to the systemic infl ammatory state observed in PE.
VEGF and sFlt1
VEGF, a potent angiogenic protein, is also a trophic cytokine 
essential for endothelial integrity. It promotes vasodilatation 
by inducing nitric oxide and prostacyclin synthesis by endo-
thelial cells. Membrane-bound fms-like tyrosine kinase 1 (Flt-
1) is a receptor for VEGF and placental growth factor (PlGF), a 
related pro-angiogenic protein. Soluble sFlt-1 is a circulating 
splice variant with antagonist activity of both VEGF and PLGF. 
sFlt-1 is produced in excessive amounts by the villous tro-
phoblast in PE that neutralizes VEGF and PlGF (18, 19). 
Exposure of early pregnancy placental villi to low oxygen 
increases HIF1-α and sFlt-1 secretion (17). Hypoxia is thus con-
sidered as one major trigger for release of sFlt-1.
Studies of genic expression profi le on preeclamptic pla-
centa have shown an up-regulation of the sFlt-1gene (18-20). 
We have also demonstrated that the preeclamptic placenta 
produced high levels of sFlt-1 in maternal circulation with in 
parallel very low levels of VEGF and PlGF (21,22). Levels of 
sFlt1 are already elevated 5 to 6 weeks before the onset of PE, 
while levels of free VEGF and PlGF are lowered. Some authors 
have also shown that urinary levels of PlGF, measured at mid-
gestation, were predictive of the subsequent onset of PE, and 
levels of sFlt-1 were directly correlated to the severity of the 
disease and inversely to the time of apparition of hypertension 
and proteinuria (23). Animal models have then been realised 
by injecting adenoviruses coding for sFlt-1 protein in gravid ro-
dents, who subsequently developed symptoms of PE (18).
VEGF also plays an important role in the glomerular ultra-
structure of the kidneys as well as in the fenestrations of the 
glomerular endothelial cells (24).
Anti-VEGF antibodies and sera from preeclamptic patients 
induce a change in the proteic expression profi le at the surface 
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of the glomerular podocytes, which is responsible for the al-
teration of the fi ltration capacity and thus of the proteinuria 
(25-27). In mice selectively heterozygous for VEGF expression 
on the podocytes, a decrease of 50% of the VEGF expression is 
responsible for proteinuria and glomerular endotheliosis (28). 
Other examples exist describing hypertension and proteinuria 
as side effects of anti-VEGF therapies (29,30).
Soluble Endoglin
Endoglin is a membranous co-receptor for Transfoming 
Growth Factor-β 1 and 3 (TGF-β1 and 3). It is highly expressed 
by endothelial cells but also by syncitiotrophoblast (32,33). Re-
cent studies have shown that Endoglin was located in caveolae 
where it can associate with endothelial NO synthase (eNOS) in 
order to regulate vascular tone (34). Other studies have dem-
onstrated its role not only in cardiovascular development but 
also in preservation of vascular homeostasis (35).
Soluble Endoglin (sEndoglin) has recently been described 
in sera from pregnant women and is considerably elevated in 
sera of preeclamptic patients, where its levels are correlated 
with the severity of the disease (36). Similarly, overexpression 
of sEndoglin in gravid rodents leads to the onset of symptoms 
of PE as well as the development of the typical associated le-
sions (renal endotheliosis, infarcts in the placenta and liver and 
schizocytes in peripheral blood). Other authors have shown 
that levels of sEndoglin were elevated already 2 to 3 months 
before the onset of the disease (37). 
Renin-Angiotensin system (RAS)
RAS is a physiological hormonal and enzymatic system lo-
cated in the kidney and regulating hydro-sodium balance and 
arterial blood pressure. Angiotensin 2 (AT-2) is one of the mean 
mediators and it is a powerful vasoconstrictor. Numbers of au-
thors describe the implication of this system in the pathogen-
esis of PE and different mechanisms are proposed.
First, RAS is not only expressed in the kidney but also in the 
trophoblast (38, 39). Then, excessive activation of RAS in the 
placenta could explain global vascular dysregulation observed 
in PE (elevated vascular tone, hypertension, endothelial dys-
function and hypersensitivity to AT-2) (40).
A mechanism of hyperactivation of RAS, described in 2001, 
consists in very high levels of AT-1 receptor/Bradykinin het-
erodimer in preeclamptic patients. Those heterodimers lead to 
an hypersensitivity to AT-2 as well as a resistance of the AT-1 
receptors (ATR-1: angiotensin II receptors), to the inactivation 
by oxygen free radicals (41).
Recent studies propose another mechanism for the hyper-
activation of the RAS in PE. Activating auto-antibodies against 
ATR-1 have been detected in sera of preeclamptic patients and 
they cannot be detected in sera of normotensive pregnant 
women (42). Generation of these auto-antibodies could be sec-
ondary to the placental ischaemia, to the vascular damages or 
to the systemic infl ammatory state. AT-2 and auto-antibodies 
against AT1-R could also contribute to an increased secretion 
of pro-infl ammatory cytokines, oxygen free radicals and to an 
excessive infl ammatory response via NADPH oxydase activa-
tion (42). These auto-antibodies increase the release of sFlt-1 
by trophoblastic cells, via activation of the AT1-R (43-45). The 
same authors have recently described a murine model of PE, 
by injecting auto-antibodies against AT1-R to pregnant mice, 
and this phenomenon was inhibited by simultaneous injection 
of Losartan which is an antagonist of AT1-R (44). These data 
indicate that the secretion of sFlt-1 by trophoblast could not 
only be induced by hypoxia but also by other signalisation cas-
cades. Similarly, hypoxia related to the defi cient placental per-
fusion could induce a powerful infl ammatory effect, responsible 
of the production of the auto-antibodies against AT1-R. These 
antibodies could in turn contribute to the defective placental 
invasion and to the increase of hypoxia and to a systemic in-
fl ammatory state. In this hypothesis, excessive production of 
sFlt-1 and sEndoglin by trophoblast would not be the “end of 
the story”, but these anti-angiogenic factors would be part of a 
complex and multi-factorial response to a defective placenta-
tion or to an immunological dysfunction.
Link between the two stages: oxidative stress and 
infl ammation?
Defective placentation observed in the fi rst stage of PE is 
responsible of an intermittent blood fl ow in the inter-villous 
chamber, with consequently an “ischaemia-reperfusion” phe-
nomenon that leads to oxidative stress and to the release of 
oxygen free radicals (46). 
Normal pregnancy is also associated with an increase in 
oxygen free radicals but the protective mechanisms are re-
inforced so that the “oxidative balance” is equilibrated. In PE, 
protective mechanisms, including anti-oxydative vitamins and 
enzymatic systems, are insuffi cient or inadequate, so that the 
balance is in favour of the oxidative stress and the subsequent 
release of pro-infl ammatory cytokines (47). Anti-oxidative 
therapies could thus prevent the onset of PE but a lot of stud-
ies have examined this hypothesis, with controversy (48-50).
As to the oxidative stress, all pregnancies present a degree 
of systemic infl ammation (52). In PE, some authors have dem-
onstrated an excessive systemic infl ammatory response (51) 
as well as increased levels of pro-infl ammatory cytokines as 
Tumor Necrosis Factor-α (TNF-α), IL-6 and -8 in sera of pre-
eclamptic patients (52,53). Systemic infl ammation could thus, 
in addition to hypoxia, be a powerful stimulus of the excessive 
release of sFlt-1 in PE (54). Indeed, some have demonstrated 
that Lipopolysaccharide (LPS) could stimulate transcription of 
HIF-1α, even in normoxic conditions (55). A lot of other pro-
infl ammatory factors have been described as activator of HIF-
1α (NF-κB, thrombin and oxygen free radicals) (54). Production 
of sEndoglin, also dependent of HIF-1α, can also be stimulated 
by these cytokines like Interferon-γ or TNF-α, in normoxic con-
ditions (56). Initial placental disease leading to PE could thus 
be the oxidative stress alone more than hypoxia. Oxidative 
stress has a pro-infl ammatory effect mediated by oxygen free 
radicals and could lead to excessive production of sFlt-1 and 
sEndoglin. Consequently, PE could in fact be more than an en-
dothelial disease but the consequence of a systemic excessive 
infl ammatory response (57).
CONCLUSION
PE is a complex disorder with a range of clinical presen-
tations. This heterogeneity suggests the possibility of varied 
pathogenic mechanisms. The initial etiologic factors are not 
well understood, nor are the interactions between the isch-
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aemic placenta, sFlt-1, sEng, and other infl ammatory cytokines 
such as TNF-α, lipid peroxides and angiotensin II, angiotensin II 
type I receptors, all of which are implicated in PE.
Even with our growing knowledge of the pathogenesis of 
PE, treatment options remain limited. A promising approach is 
the early detection from week 11 to 13 of the severe and pre-
cocious forms of the disease. This would allow closer surveil-
lance and may lead to prophylactic approaches that will require 
targeted therapies. The ability to prolong pregnancy safely with 
these therapies, even for a short period of time, potentially 
could make a signifi cant improvement in morbidity.
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